Details

Autor(en) / Beteiligte

• Togashi, Kyo
• Hatakeyama, Shingo
• Okamoto, Teppei
• Kojima, Yuta
• Iwamura, Hiromichi
• Fujita, Naoki
• Narita, Takuma
• Hamano, Itsuto
• Hamaya, Tomoko
• Yoneyama, Tohru
• Yamamoto, Hayato
• Yoneyama, Takahiro
• Hashimoto, Yasuhiro
• Ohyama, Chikara

Titel

Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥75 years

Ist Teil von

• Urologic oncology, 2021-10, Vol.39 (10), p.729.e17-729.e25

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• •As global life expectancy increases, benefits of robot-assisted radical prostatectomy (RARP) in older adult patients with prostate cancer require further investigation.•We aimed to evaluate oncologic outcomes, patient-reported outcomes (PROs), and frailty in 752 older adult patients aged ≥75 years who underwent RARP.•No significant differences were observed in the oncological outcomes, PROs, and pad-free rates regardless of age groups.•The oncologic outcomes and PROs in select patients with prostate cancer aged ≥75 years were feasible and acceptable with RARP. The present study aimed to evaluate oncologic outcomes, patient-reported outcomes (PROs), and frailty in older adult patients aged ≥75 years who underwent robot-assisted radical prostatectomy (RARP). This retrospective study reviewed the medical records of 752 patients who underwent RARP from July 2011 to May 2020. The PROs were evaluated by Expanded Prostate Cancer Index Composite questionnaire at baseline and 1 year after RARP. Patients were divided into 3 groups according to age at RARP: <70, 70–74, and ≥75 years. Oncologic outcomes and PROs were compared between the ≥75 and 70–74 years groups and between the ≥75 and <70 years groups. Median follow up was 47 months. Of the 752 patients, 469, 216, and 74 were classified into the <70, 70–74, and ≥75 years groups, respectively. No significant differences were observed in the biochemical recurrence-free survival, cancer-specific survival, and overall survival among the groups. No significant differences were observed in the PROs and pad-free rates at baseline and 1 year after RARP among the groups. The full satisfaction (Expanded Prostate Cancer Index Composite score = 100) at 12 months after RARP was significantly higher in the ≥75 years group (27%) than in the <70 years group (15%, P = 0.045). The oncologic outcomes and PROs in select patients with prostate cancer aged ≥75 years were feasible and acceptable with RARP. [Display omitted]